1.02

0.96% -0.02

Bright Minds Biosciences Inc (DRUG)

Overview News Price History Discussions Forecast Stock Split

Bright Minds Biosciences Inc stock is currently priced at $1.02, with a 24-hour trading volume of 2,149. It has seen a -0.96% decreased in the last 24 hours and a -25.36% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.04 pivot point. If it approaches the $0.9567 support level, significant changes may occur.

Previous Close:

$1.04

Open:

$1.01

24h Volume:

2,149

Market Cap:

$4.64M

Revenue:

Net Income/Loss:

$-4.98M

P/E Ratio:

-0.5256

EPS:

-1.9408

Net Cash Flow:

$-3.85M

1W Performance:

-5.50%

1M Performance:

-25.36%

6M Performance:

-23.13%

1Y Performance:

+71.67%

1D Range:

$1.00

$1.01

52W Range:

$0.4791

$6.44

Bright Minds Biosciences Inc Stock (DRUG) Company Profile

Name

Bright Minds Biosciences Inc

Sector

Healthcare (1193)

Industry

Biotechnology (685)

Phone

647 407 2515

Address

19 Vestry Street, New York

Employee

Twitter

Next Earnings Date

Latest SEC Filings

DRUG's Discussions on Twitter

Bright Minds Biosciences Inc Stock (DRUG) Financials Data

Bright Minds Biosciences Inc (DRUG) Net Income 2024

DRUG net income (TTM) was -$4.98 million for the quarter ending December 31, 2023, a +48.22% increase year-over-year.

Bright Minds Biosciences Inc (DRUG) Cash Flow 2024

DRUG recorded a free cash flow (TTM) of -$3.85 million for the quarter ending December 31, 2023, a +55.61% increase year-over-year.

Bright Minds Biosciences Inc (DRUG) Earnings per Share 2024

DRUG earnings per share (TTM) was -$1.3177 for the quarter ending December 31, 2023, a +63.68% growth year-over-year.

Bright Minds Biosciences Inc., a biotechnology company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.